Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health SystemNovo Nordisk A/S (NYSE:NVO) has disclosed that it retains approximately 60% of the list price of its diabetes and obesity medications, Ozempic and Wegovy, in the U.S. after accounting for rebates and fees paid to intermediaries.This revelation comes amid intensifying scrutiny over the cost of these…
